New drug targets genetic weakness in Hard-to-Treat uterine cancer
NCT ID NCT07522697
First seen Apr 15, 2026 · Last updated May 06, 2026 · Updated 3 times
Summary
This study tests a drug called Inavolisib in about 48 women with advanced endometrial cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if the drug can shrink tumors or slow cancer growth. Participants must have tried other treatments first and have a confirmed PIK3CA mutation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Institute of Napoli, Division of Medical Oncology - Uro-Gynecology Department
Naples, 80131, Italy
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.